Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial

2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This vaccine consists of two plasmids expressing CMV antigens glycoprotein B (gB) and phosphoprotein 65 (pp65) formulated with a CRL1005 poloxamer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Larry R., Wloch, Mary K., Chaplin, Jennifer A., Gerber, Michele, Rolland, Alain P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494211/
https://www.ncbi.nlm.nih.gov/pubmed/26344340
http://dx.doi.org/10.3390/vaccines1040398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494211/
https://www.ncbi.nlm.nih.gov/pubmed/26344340
http://dx.doi.org/10.3390/vaccines1040398

Ejemplares similares